OmniSeq Immune Report Card® Assay
An assay which supports immunotherapy treatment decision making by providing comprehensive immune profiling from a single specimen.
Understand the Immune Response Beyond PD-L1, MSI and Mutational Burden
The Immune Report Card assay
- measures multiple immune biomarkers present in DNA, RNA, proteins, and cells to comprehensively interrogate the cancer-immunity cycle.1 Single biomarker assays only evaluate one or two steps in the immune cycle and thus may miss the complete picture.
- includes FDA-approved PD-L1 IHC, microsatellite instability (MSI), tumor mutational burden, and gene expression of 54 specific immune markers related to tumor infiltrating lymphocytes and T-cell receptor signaling.2
- uses five different testing methodologies and the results are consolidated into one summary report personalized for a patient’s immune profile and potential immunotherapy treatment options.
Immunotherapy Actionability by Biomarker Assessment
~50% of patients with negative results by standard markers had high expression of secondary immune markers. These overexpressed markers are direct targets for therapies commercially available or in clinical trials.
Please see the test menu for additional specimen and test information.
The OmniSeq Comprehensive® assay was developed by OmniSeq® and is performed by OmniSeq as a send-out from Integrated Oncology, part of LabCorp Specialty Testing Group, its US distributor.
1. Chen, DS, Mellman, I, Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity 2013; 39:1-10. 2. OmniSeq, copyright 2017.